[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corneal-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corneal-ulcer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,72,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100566655","phase-3-fungal-ulcer-treatment-augmented-with-natamycin-and-cyclosporine-a-100566655",false,"NCT06658002","Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A","FANCY","Inclusion Criteria:\n\n* Inclusion is based on presenting acuity, not ulcer size.\n* Inclusion of 20\u002F40 = 6\u002F12 = 0.3 Log MAR and 20\u002F400 = 3\u002F60 = +1.3 Log MAR.\n* Smear or culture positive for fungal keratitis, any length.\n* Age 18 years.\n* Willing to participate in study.\n\nExclusion Criteria:\n\n* Co-infection with bacterial or viral keratitis.\n* Corneal perforation.\n* Requiring therapeutic keratoplasty for fungal keratitis.\n* Unwilling or unable to follow up (e.g., living too far from hospital).\n* Presenting acuity better than 20\u002F40 = 6\u002F12 = 0.3 Log MAR or worse than 20\u002F400 = 3\u002F60 = +1.3 Log MAR.\n* Subjects taking cyclosporine at any concentration on presentation.\n* Acuity worse than 20\u002F200 = 6\u002F60 = +1.0 Log MAR in unaffected eye.\n* Pregnant women.\n* Penetrating Keratoplasty.\n* Presents with a 0-7 day history of topical steroid.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.",[26,27],"Fungal Keratitis","Corneal Ulcer",[27,29,26,30],"Cyclosporine A","Fungal Corneal Ulcer","RECRUITING","2026-06-03",{"date":34,"type":35},"2026-06-05","ACTUAL",{"date":37,"type":35},"2025-09-01",{"date":39,"type":20},"2027-09-01",{"name":41,"class":42},"University of California, San Francisco","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100621968","follow-up-compliance-for-corneal-ulcer-patients-with-sms-reminder-100621968","NCT07377513","Follow-up Compliance for Corneal Ulcer Patients With SMS Reminder","Follow-up Compliance for Medically Managed Corneal Ulcer Patients With SMS Reminders in a Tertiary Eye Care Setting in Western Nepal: A Quasi Experimental Study","Inclusion Criteria:\n\n* Newly diagnosed patients (18 to 70 years) of corneal ulcer in one or both eye, who are medically managed, visiting the OPD at LEIRC and have access to a mobile phone.\n\nExclusion Criteria:\n\n* Less than 18 years or more than 70 years Patients who do not have a access to a mobile phone.","70 Years",{"count":53,"type":20},310,[55],"NA","Corneal ulcer is defined as the loss of corneal epithelium with underlying stromal infiltration and suppuration, accompanied by signs of inflammation, with or without hypopyon1. The condition may be caused by bacterial, fungal, viral or parasitic pathogens and carries a significant risk of corneal perforation and subsequent visual impairment2. These risks highlight the importance of timely treatment plans and consistent referral networks3.\n\nA lot of patients choose to self-medicate and postpone seeking professional assistance due either their lack of awareness or forgetfulness, which results in inadequate follow-up compliance4,5. Scheduling appointments regularly is still a significant barrier to successful treatment and visual recovery.\n\nSMS reminders have shown encouraging real-world success in improving follow-up attendance with in ophthalmology. Mobile health tools, such as the peek Community Eye Health system, have proven increased follow-up rates and improved access to eye care services in low-resource setting through automated appointment reminders and patient monitoring6.\n\nThe aim of this operational research study to evaluated the feasibility, scalability, and effectiveness of SMS reminders in improving follow-up compliance among patients with corneal ulcer at the Lumbini Eye Institute and Research Center (LEIRC), Western Nepal. The findings are expected to inform the integration of cost-effective digital health strategies to strengthen patient adherence, optimize clinical outcomes, and support eye health programs in resource limited environments.",[27],[59,60,61],"Corneal ulcer","Follow-up compliance","SMS reminder","2026-05-11",{"date":64,"type":35},"2026-05-12",{"date":66,"type":35},"2026-02-23",{"date":68,"type":20},"2027-12",{"name":70,"class":42},"Seva Canada Society",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":71},"100623255","intrastromal-moxifloxacin-as-an-adjunctive-therapy-in-recalcitrant-bacterial-keratitis-100623255","NCT07394257","Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * Clinical diagnosis of bacterial keratitis confirmed by corneal scraping and microbiology\n  * Recalcitrant keratitis defined as no significant clinical improvement after 48-72 hours of intensive topical antibiotic therapy\n  * Ability to provide written informed consent\n\nExclusion Criteria\n\n* Fungal, viral, or acanthamoeba keratitis\n* Corneal perforation or impending perforation\n* Known hypersensitivity to fluoroquinolones\n* Pregnancy or lactation\n* Immunocompromised state or current systemic immunosuppressive therapy\n* Previous intrastromal or intracameral antibiotic injection for the same episode","20 Years",{"count":80,"type":20},60,[55],"Bacterial keratitis is a potentially sight-threatening corneal infection that is commonly treated with intensive topical antibiotics. Despite appropriate therapy, some cases show inadequate clinical response, particularly when the infection involves the deep corneal stroma. Limited penetration of topical antibiotics into deeper corneal layers may contribute to treatment failure in these recalcitrant cases.\n\nIntrastromal antibiotic injection is a targeted drug-delivery approach that allows high local antimicrobial concentrations directly at the site of infection. Moxifloxacin is a broad-spectrum fluoroquinolone with proven efficacy in bacterial keratitis and favorable corneal tissue penetration. However, evidence regarding the clinical benefit and safety of intrastromal moxifloxacin as an adjunctive treatment remains limited.\n\nThis randomized controlled trial aims to evaluate the efficacy and safety of intrastromal moxifloxacin injection as an adjunct to standard topical moxifloxacin therapy compared with topical therapy alone in patients with recalcitrant bacterial keratitis. The primary outcome is time to complete clinical resolution of infection. Secondary outcomes include visual acuity improvement, ulcer healing rate, need for additional interventions, and treatment-related complications.",[84,85,27],"Bacterial Keratitis","Recalcitrant Infectious Keratitis","2026-02-01",{"date":88,"type":35},"2026-02-06",{"date":90,"type":35},"2025-10-01",{"date":92,"type":20},"2026-04-01",{"name":94,"class":42},"Minia University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":5},"100493428","phase-2-efficacy-of-locally-delivered-allogeneic-mesenchymal-stromal-cells-100493428","NCT05705024","Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells","Efficacy of Locally Delivered Allogeneic Mesenchymal Stem Cells for Promoting Corneal Repair","Inclusion Criteria:\n\nVisual Acuity:\n\n* Best corrected distance visual acuity (BCDVA) score ≤ 75 ETDRS letters, (≥ 0.2 LogMAR, ≤ 20\u002F32 Snellen or ≤ 0.625 decimal fraction) in the affected eye.\n\nOcular Health:\n\n* Patients with non-resolving corneal epitheliopathy or epithelial defect after two or more weeks of standard non-surgical treatments (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops; anti-inflammatory therapy, soft bandage contact lens).\n* No objective clinical evidence of improvement in the last 2 weeks (≤50% reduction in fluorescein staining or ≤50% reduction in longest diameter of the epithelial defect).\n* If both eyes have chronic epithelial disease, the eye with the worse epithelial disease will be treated.\n* Evidence of impaired epithelial barrier manifested by fluorescein staining of the epithelium with a score 10 or higher by National Eye Institute grading.\n* Patients with stage 1 (no epithelial defect), stage 2 (persistent epithelial defect, PED; without stromal loss) or stage 3 (corneal ulcer; with stromal loss) neurotrophic keratopathy25-27 limited to ≤80% corneal diameter.\n\nStudy Procedures:\n\n* Only patients who satisfy all Informed Consent requirements may be included in the study. The patient and\u002For his\u002Fher legal representative must read, sign and date the Informed Consent document before any study-related procedures are performed. The Informed Consent form signed by patients and\u002For legal representatives must have been approved by the IRB for the current study.\n* Patients must have the ability and willingness to comply with study procedures.\n\nExclusion Criteria:\n\nVisual Acuity:\n\n* Best-corrected distance visual acuity (BCDVA) score better than 75 ETDRS letters, or 0.2 LogMAR, or 20\u002F32 Snellen or 0.625 decimal fraction in the affected eye\n\nOcular Health:\n\n* Ocular drug toxicity less than two weeks ago\n* Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation in the affected eye.\n* History of any ocular surgery (including laser or refractive surgical procedures) in the affected eye within the three months before study enrollment. (An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the PED. Ocular surgery in the affected eye will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period unless the patient will be involved in corneal thinning of more than 1\u002F3 corneal stroma, corneal melting or perforation.\n* Prior surgical procedure(s) for the treatment of a chronic corneal epitheliopathy (e.g., complete tarsorrhaphy, conjunctival flap, etc.) in the affected eye with the exception of amniotic membrane transplantation. Patients previously treated with amniotic membrane transplantation may only be enrolled two weeks after the membrane has disappeared within the area of the chronic corneal epitheliopathy or corneal ulcer or at least six weeks after the date of the amniotic membrane transplantation procedure. Patients previously treated with Botox (botulinum toxin) injections used to induce pharmacologic blepharoptosis are eligible for enrollment only if the last injection was given at least 90 days prior to enrollment in the study.\n* Chronic corneal epitheliopathy in the background of endothelial decompensation that needs corneal graft\n* Anticipated need for punctual occlusion during the study treatment period. Patients with punctual occlusion or punctual plugs inserted prior to the study are eligible for enrollment provided that the punctual occlusion is maintained during the study.\n* Evidence of corneal ulceration involving the posterior third of the corneal stroma, corneal melting or perforation in the affected eye.\n* Presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (e.g., progressive or degenerative corneal or retinal conditions, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases).\n* Patients with uncontrolled eyelid abnormality that preclude appropriate eyelid closure or including eyelash abnormality\n\nStudy Procedures:\n\n* Known hypersensitivity to one of the components of the study or procedural medications (e.g., fluorescein).\n* History of drug, medication or alcohol abuse or addiction.\n* Use of any investigational agent within 4 weeks of screening visit.\n* Participation in another clinical study at the same time as the present study.\n* Participants who are pregnant at the time of study enrollment will be excluded; pregnancy is identified according to the patient's self-report \u002Fpositive βhCG",{"count":103,"type":20},38,[105],"PHASE2","The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.",[27],"2025-12-13",{"date":110,"type":35},"2025-12-16",{"date":112,"type":35},"2023-09-29",{"date":114,"type":20},"2026-09-28",{"name":116,"class":42},"University of Illinois at Chicago"]